SCHEMBL872959

SCHEMBL872959

COC(=O)C1CC(=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL536252 0.91 BRD4 (0.50)
SCHEMBL2670790 0.91 BRD4 (0.50)
SCHEMBL1650294 0.91 BRD4 (0.50)
SCHEMBL1650296 0.83 BRD4 (0.44)
SCHEMBL6370539 0.83 BRD4 (0.44)
SCHEMBL24035543 0.82 CHRNB2 (0.57)
SCHEMBL1139285 0.82 BRD4 (0.47)
SCHEMBL17014460 0.82 BRD4 (0.47)
SCHEMBL4868550 0.82 BRD4 (0.47)
SCHEMBL24483210 0.81 CHRNB2 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 613 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118561689-B Preparation method of 3-oxo-cyclobutanecarboxylic acid ester compound 中节能万润股份有限公司 2024-11-22 CN claimed
CN-116813529-A Synthesis method of 6-tert-butoxycarbonyl-2-amino-6-azaspiro [3.4] octane 安顺市人民医院 2023-09-29 CN claimed
WO-2026107328-A1 AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS SEPTERNA, INC. (US) 2026-05-21 WO disclosed
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2026-05-21 US disclosed
EP-4735449-A1 TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE OmniAB, Inc. (US) 2026-05-06 EP disclosed
US-20260102383-A1 LPAR1 Inhibitors ABBVIE INC (US) 2026-04-16 US disclosed
US-20260092050-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2026-04-02 US disclosed
CN-121652071-A Synthesis method of 3-oxo-1-cyclobutanecarboxylic acid 西南化工研究设计院有限公司 2026-03-13 CN disclosed
US-20260070901-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTPR LTD (GB) 2026-03-12 US disclosed
US-12570626-B2 Degraders and degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
EP-4448492-B1 COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER REGLAGENE INC (US) 2026-03-04 EP disclosed
US-20070129388-A1 Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid PFIZER, INC. 2007-06-07 US disclosed
US-6291520-B1 INHIBIT THE ENZYME LIPOXYGENASE; TREATMENT OR ALLEVIATION OF INFLAMMATORY DISEASES, ALLERGIC CONDITIONS AND CARDIOVASCULAR DISEASES PFIZER 2001-09-18 US disclosed
US-6054448-A TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM. ELI LILLY AND COMPANY LIMITED (GB) 2000-04-25 US disclosed
EP-0837061-A1 Pharmaceutical acidic compounds ELI LILLY AND COMPANY LIMITED (GB) 1998-04-22 EP disclosed
US-5691351-A Bis-(Heteroarylmethoxyphenyl)cycloalkyl carboxylates as inhibitors of leukotriene biosynthesis ABBOTT LABORATORIES (US) 1997-11-25 US disclosed
WO-1997029090-A1 BIS-(HETEROARYLMETHOXYPHENYL)CYCLOALKYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF LEUKOTRIENE BIOSYTHESIS ABBOTT LABORATORIES (US) 1997-08-14 WO disclosed
EP-0559743-B1 NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE PFIZER (US) 1995-03-08 EP disclosed
EP-0559743-A1 NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE. PFIZER HOSPITAL PROD (US) 1993-09-15 EP disclosed
WO-1992009566-A1 NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE PFIZER INC. (US) 1992-06-11 WO disclosed